Electroconvulsive therapy or ketamine? Clinical factors affect outcomes

Electroconvulsive therapy or ketamine? Clinical factors affect outcomes retrieved 26 June 2024 from https://medicalxpress.com/news/2024-06-electroconvulsive-therapy-ketamine-clinical-factors.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Jan 31, 2024Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapyA research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.
Source: NewsMedical - 🏆 19. / 71 Read more »

People coming off antidepressants are looking for help online, underscoring a gap in traditional clinical practicesFor many people, antidepressants are a lifesaving treatment.
Source: medical_xpress - 🏆 101. / 51 Read more »

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trialA recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer's disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.
Source: NewsMedical - 🏆 19. / 71 Read more »